JP Morgan Chase
EBS icon

JP Morgan Chase’s Emergent Biosolutions EBS Stock Holding History

JP Morgan Chase’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,500
Closed -$800K – 5825
2018
Q4 		$800K Buy
+13,500
New +$870K ﹤0.01% 3878

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

JP Morgan Chase's EBS Position: Q2 2026 in Review

JP Morgan Chase increased its Emergent Biosolutions (EBS) stake by 14% in Q2 2026, buying an estimated $24.5K and bringing the position to 24,473 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #5596.

JP Morgan Chase first reported a position in EBS in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.9M in Q3 2020. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • JP Morgan Chase held 24,473 shares of Emergent Biosolutions worth $207K as of Q2 2026.
  • JP Morgan Chase bought 2,932 Emergent Biosolutions shares in Q2 2026, an estimated $24.5K.
  • Emergent Biosolutions made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5596 holding.
  • JP Morgan Chase first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Emergent Biosolutions position peaked at $19.9M in Q3 2020.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.